紫杉醇脂质体(Memorial Sloan Kettering Cancer Center)(Paclitaxel Liposomal(Memorial Sloan Kettering Cancer Center))

概要

基本信息

药物类型

小分子化药、脂质体药物

别名

PNU-93914

靶点

Tubulin

作用方式

抑制剂

作用机制

微管蛋白抑制剂

治疗领域

肿瘤消化系统疾病

在研适应症-

非在研适应症

转移性食管癌

原研机构

Memorial Sloan Kettering Cancer Center

在研机构-

非在研机构

Memorial Sloan Kettering Cancer Center

权益机构-

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

9

项与紫杉醇脂质体(Memorial Sloan Kettering Cancer Center) 相关的临床试验

NCT05691010

/ Recruiting早期临床1期IIT

A Feasibility Study of Integrated Delivery of Hypofractionated Pelvic IMRT With Carboplatin and Paclitaxel in Stage III Copy-Number Low and Copy-Number High Subtypes of Endometrial Cancer

The purpose of this study is to find out whether short-course radiation therapy (1 week instead of the usual 5 weeks) with chemotherapy (carboplatin and paclitaxel) is practical (feasible), meaning that most participants are able to complete the treatment schedule.

开始日期2023-01-10

申办/合作机构

Memorial Sloan Kettering Cancer Center

NCT04722523

/ Recruiting临床1期IIT

A Pilot Study of Neoadjuvant Cemiplimab With Platinum-Doublet Chemotherapy, and Cetuximab in Patients With Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

The purpose of this study is to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a safe treatment for head and neck cancer, and whether receiving this combination treatment before surgery may allow participants to forgo the standard radiation treatment after surgery.

开始日期2021-01-20

申办/合作机构

Memorial Sloan Kettering Cancer Center

[+1]

NCT03085056

/ Active, not recruiting早期临床1期IIT

A Pilot Study of Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

The purpose of this study is to test the safety and tolerability of this treatment combination of paclitaxel and trametinib. Additionally, this study aims to to find out what effects the combination of paclitaxel and trametinib has on the shrinkage and growth of anaplastic thyroid cancer.

开始日期2017-03-15

申办/合作机构

Memorial Sloan Kettering Cancer Center

[+1]

100 项与紫杉醇脂质体(Memorial Sloan Kettering Cancer Center) 相关的临床结果

登录后查看更多信息

100 项与紫杉醇脂质体(Memorial Sloan Kettering Cancer Center) 相关的转化医学

登录后查看更多信息

100 项与紫杉醇脂质体(Memorial Sloan Kettering Cancer Center) 相关的专利（医药）

登录后查看更多信息

100 项与紫杉醇脂质体(Memorial Sloan Kettering Cancer Center) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性食管癌	临床2期	美国	Memorial Sloan Kettering Cancer Center	2000-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NRG GY018 (SGO2024)	N/A	子宫内膜癌 PD-L1 \| dMMR \| pMMR	-	Pembrolizumab plus carboplatin/paclitaxel	構廠獵憲簾鬱餘憲蓋窪(積醖壓艱範壓製選衊淵) = 糧蓋製鹹憲鹹網獵網窪餘鏇構積膚顧壓艱構範 (鏇網膚顧餘鏇窪鹽壓蓋 )	-	2024-11-01
				Carboplatin/paclitaxel plus placebo	構廠獵憲簾鬱餘憲蓋窪(積醖壓艱範壓製選衊淵) = 顧製繭膚艱簾蓋夢鹹窪餘鏇構積膚顧壓艱構範 (鏇網膚顧餘鏇窪鹽壓蓋 )
TBCRC033 (SABCS2020)	N/A	闭经辅助 premenopausal	512	T-DM1 arm	簾夢製餘鹹壓簾餘鹹壓(憲鹽憲繭製鑰製築製製) = 夢夢範壓餘蓋繭網衊窪壓餘壓餘構獵範夢積壓 (鑰積糧廠顧觸醖窪簾壓 ) 更多	-	2020-02-15
				TH arm	簾夢製餘鹹壓簾餘鹹壓(憲鹽憲繭製鑰製築製製) = 淵襯艱憲遞範蓋襯醖築壓餘壓餘構獵範夢積壓 (鑰積糧廠顧觸醖窪簾壓 ) 更多
GOG 186H (SGO2016)	临床2期	复发性原发性腹膜癌维持 CA-125	108	Paclitaxel 80 mg/m2	選範繭壓簾窪壓選構鹹(窪膚構糧醖糧願蓋獵膚): HR = 0.945 (95% CI, 0.625 ~ 1.428) 更多	不佳	2016-06-01
				Paclitaxel + Reolysin 3 × 10^10 TCID50
NCT00807573 (CTgov)	临床2期	晚期非小细胞肺癌	44	Paclitaxel+Pemetrexed+Bevacizumab	廠夢鑰窪壓憲糧構淵鬱 = 顧網獵夢艱鏇衊憲繭醖糧壓襯襯願壓獵鬱艱餘 (鏇膚糧蓋顧艱鏇糧蓋鏇, 繭選壓構艱顧鏇衊選廠 ~ 淵壓願願糧襯積顧廠鏇) 更多	-	2015-12-30